Equities analysts expect Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) to announce ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Entasis Therapeutics’ earnings. The lowest EPS estimate is ($0.38) and the highest is ($0.32). Entasis Therapeutics posted earnings per share of ($1.15) during the same quarter last year, which suggests a positive year over year growth rate of 70.4%. The company is scheduled to issue its next earnings results on Thursday, May 6th.
On average, analysts expect that Entasis Therapeutics will report full-year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.36) to ($1.21). For the next year, analysts anticipate that the firm will post earnings of ($1.45) per share, with EPS estimates ranging from ($1.95) to ($0.83). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Entasis Therapeutics.
Entasis Therapeutics (NASDAQ:ETTX) last posted its quarterly earnings data on Monday, March 22nd. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.26.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC increased its holdings in Entasis Therapeutics by 478.9% in the fourth quarter. Virtu Financial LLC now owns 146,128 shares of the company’s stock worth $361,000 after buying an additional 120,887 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Entasis Therapeutics in the fourth quarter worth approximately $147,000. Jaffetilchin Investment Partners LLC acquired a new position in Entasis Therapeutics in the fourth quarter worth approximately $27,000. Renaissance Technologies LLC increased its holdings in Entasis Therapeutics by 110.3% in the fourth quarter. Renaissance Technologies LLC now owns 506,389 shares of the company’s stock worth $1,251,000 after buying an additional 265,548 shares during the last quarter. Finally, Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in Entasis Therapeutics in the fourth quarter worth approximately $2,915,000. 27.55% of the stock is owned by institutional investors and hedge funds.
NASDAQ:ETTX opened at $2.05 on Monday. Entasis Therapeutics has a twelve month low of $1.58 and a twelve month high of $4.25. The company has a 50-day moving average of $2.63 and a 200-day moving average of $2.40. The firm has a market cap of $76.49 million, a price-to-earnings ratio of -0.61 and a beta of 2.10.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.